Blood and lymphatic system disorders: Bone marrow depression including neutropenia, eosinophilia, leukopenia, agranulocytosis has been reported. Fatalities with carbimazole-induced agranulocytosis have been reported. Rare cases of pancytopenia/aplastic anaemia and isolated thrombocytopenia have also been reported. Additionally, very rare cases of haemolytic anaemia have been reported.
Patients should always be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever, malaise and should be instructed to stop the drug and to seek medical advice immediately. In such patients, blood cell counts should be performed immediately, particularly where there is any clinical evidence of infection.
Nervous system disorders: Headache.
Gastro-intestinal system disorders: Nausea, mild gastric distress. Loss of sense of taste has been observed.
General disorders and administration site conditions: Fever, Malaise.
Hepato-biliary system disorders: Hepatic disorders, including abnormal liver function tests, hepatitis, cholestatic hepatitis, cholestatic jaundice and most commonly jaundice, have been reported: in these cases carbimazole should be withdrawn.
Injury, poisoning and procedural complications: Bruising.
Skin and subcutaneous tissue disorders: Skin rashes, pruritus, urticaria. Hair loss has been occasionally reported.
Musculoskeletal system disorders: Isolated cases of myopathy have been reported. Patients experiencing myalgia after the intake of NeoMercazole should have their creatine phosphokinase levels monitored.
Hypersensitivity and allergic reaction: Angioedema and multi-system hypersensitivity reactions such as cutaneous vasculitis, liver, lung and renal effects occur.
Vascular Disorders: Bleeding.
View ADR Monitoring Form